**Current Topics**

**Recent Advances in Research on Vascular Permeability to Establish Novel Therapeutic and Drug Delivery Strategies for Intractable Diseases**

**Review**

**Vascular Leakage Prevention by Roundabout 4 under Pathological Conditions**

Keisuke Shirakura and Yoshiaki Okada

*Max Planck Institute for Molecular Biomedicine; Münster 48149, Germany; and Graduate School of Pharmaceutical Sciences, Osaka University; Osaka 565–0871, Japan.

Received May 12, 2021

Vascular permeability is regulated mainly by the endothelial barrier and controls vascular homeostasis, proper vessel development, and immune cell trafficking. Several molecules are involved in regulating endothelial barrier function. Roundabout 4 (Robo4) is a single-pass transmembrane protein that is specifically expressed in vascular endothelial cells. Robo4 is an important regulator of vascular leakage and angiogenesis, especially under pathological conditions. The role of Robo4 in preventing vascular leakage has been studied in various disease models, including animal models of retinopathy, tumors, diabetes, and endotoxemia. The involvement of Robo4 in vascular endothelial growth factor and inflammation-mediated signaling pathways has been well studied, and recent evidence suggests that Robo4 modulates endothelial barrier function via distinct mechanisms. In this review, we discuss the role of Robo4 in endothelial barrier function and the underlying molecular mechanisms.

**Key words** angiogenesis; endothelial permeability; Roundabout 4; vascular leakage

1. INTRODUCTION

Vascular endothelial cells present on the inner surface of blood vessels act as a barrier that restricts the movement of fluid, molecules, and immune cells. Endothelial barrier function is regulated by cell junctions and cytoskeleton molecules. At cell junctions, the adjacent cells are connected by adherens junction proteins such as vascular endothelial (VE)-cadherin and tight junction proteins such as claudin family proteins. The actin cytoskeleton is connected to cell junction proteins and generates a pulling force via reorganization. Various molecules, such as growth factors and inflammatory cytokines, affect the integrity of the endothelial barrier. The dynamics and plasticity of the endothelial barrier are essential for vascular homeostasis, vascular development, and immune function. Dysfunction of the endothelial barrier is associated with several diseases.

Roundabout 4 (Robo4), a single-pass transmembrane protein belonging to the Roundabout family of proteins. Other Roundabout proteins are predominantly expressed in neural cells and are involved in axon guidance. Robo4 was identified using bioinformatics data mining as an endothelial cell-specific Roundabout family protein. Subsequent studies have confirmed the specific expression of Robo4 in vascular endothelial cells. Robo4 stabilizes the vasculature, particularly under pathological conditions. In cultured endothelial cells, Robo4 suppresses cell migration, proliferation, and tube formation. Studies have also shown that Robo4 is required for proper vasculature development in zebrafish. Although mice lacking Robo4 do not show apparent defects in developmental angiogenesis, loss of Robo4 induces pathological angiogenesis in various other disease models, including those of hypoxia-induced retinopathy and cancer. Robo4 expression is upregulated under several pathological conditions, confirming the protective role of this protein.

Several studies have confirmed the role of Robo4 in stabilizing vascular endothelial cells; however, the underlying molecular mechanisms remain controversial. Recent studies on the role of Robo4 in preventing vascular hyperpermeability using various pathological models demonstrated that Robo4 regulates vascular permeability via distinct mechanisms. This review discusses the present knowledge of Robo4-mediated regulation of vascular permeability and highlights the biological functions of this protein.

2. ROBO4 SUPPRESSES VASCULAR LEAKAGE UNDER PATHOLOGICAL CONDITIONS

Mice lacking Robo4 are viable and show slightly increased vascular permeability under basal conditions. In several disease models, such as those of hypoxia-induced retinopathy, cancer, diabetes, and endotoxemia, studies have shown that lack of Robo4 leads to more severe vascular leakage. Robo4 stabilizes endothelial permeability by regulating both adherens junctions and tight junctions in endothelial cells. Adherens junctions are involved in the transmigration of cancer and immune cells, and lack of Robo4 enhances lung metastasis of cancers and diabetes of immune cells. In vitro studies have shown that Robo4 suppresses endothelial hyperpermeability induced by various stimuli such as vascular endothelial growth factor (VEGF), interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α), and histamine. Recent evidence suggests that Robo4 regulates endothelial permeability through several distinct mechanisms.
3. MOLECULAR MECHANISM UNDERLYING ROBO4-MEDIATED REGULATION OF VASCULAR PERMEABILITY

3.1. Robo4 and Robo1 Cause Internalization of VEGF Receptor 2 (VEGFR2)  
The first proposed model to explain the mechanism underlying Robo4-mediated regulation of vascular permeability suggests that Robo4 acts as a co-receptor. SLIT family proteins (SLITs) were initially proposed as potential ligands of Robo4, as they are well-known ligands for Robo1 and Robo2 in the central nervous system. In the vascular system, SLITs play both pro- and anti-angiogenic roles via VEGFR2. VEGFR2 is a central player in the VEGF signaling pathway that promotes angiogenesis and induces vascular leakage. Robo1 and Robo2 are responsible for the pro-angiogenic functions of SLITs via enhanced VEGF-VEGFR2 signaling, whereas Robo4 does not participate in the pro-angiogenic functions of SLITs. In contrast, Robo1, Robo2, and Robo4 regulate the anti-angiogenic functions of SLITs via VEGFR2 internalization. Previously, the interaction between Robo4 and SLITs was studied using cell-based assays. However, ex vivo studies using recombinant proteins demonstrated that Robo4 does not directly interact with SLIT2. Structural analysis also revealed that Robo4 lacks essential amino acid residues for SLIT2 binding. These studies suggest that Robo4 indirectly modulates signaling cascades triggered by SLITs. Robo family receptors interact with each other to form multimers. Robo4 binds to Robo1 and affects SLIT2-mediated Robo1 function. Therefore, it is possible that Robo4 modulates the anti-angiogenic functions of SLITs by binding to Robo1 (Fig. 1).

3.2. Robo4 Suppresses VEGF Phosphorylation by Activating Unc5B  
The second model assumes that Robo4 acts as a membrane-associated ligand of Unc5B. Although Robo4-Fc, a chimeric protein of the Robo4 extracellular domain and Fc region of human immunoglobulin G, suppresses angiogenesis in pathological conditions, it does not bind to SLITs. This finding indicates that the Robo4 extracellular domain binds to unknown partners. A high-throughput screening assay identified Unc5B as an interacting partner of the Robo4 extracellular domain. Unc5B is a member of the Unc5 receptor family, which regulates axon guidance by binding to Netrin-1. Unc5B is predominantly expressed in the vascular system, and interfering with Unc5B expression causes vascular defects during developmental and adult stages. The Robo4 extracellular domain binds to Unc5B and induces an intracellular signaling cascade to suppress VEGF-mediated vascular leakage. Robo4-Unc5B axis suppresses the activation of VEGFR2 by reducing the phosphorylation of VEGFR2 Y951 (Y949 in mouse) but not Y1175. On the other hand, phosphorylation of VEGFR2 Y951 is responsible for vascular hyperpermeability via the T cell-specific adaptor (TSAd) and Src. On the other hand, phosphorylation of VEGFR2 Y1175 plays an essential role in developmental vasculogenesis and angiogenesis. These limited effects of Robo4 on VEGFR2 activation may explain why Robo4 does not affect vasculogenesis and angiogenesis during development. To address the role of Robo4-Unc5B signaling in vivo, mice expressing the mutant Robo4 lacking the intracellular domain were developed. Interestingly, this Robo4 mutant attenuated the vascular leakage induced by VEGF, but not histamine. Taken together, these studies suggest that Robo4 functions as a ligand of Unc5B and selectively attenuates VEGF-VEGFR2 signaling (Fig. 2).
3.3. Robo4 Stabilizes Cellular Junctions by Regulating the Subcellular Localization of TNF Receptor-Associated Factor 7 (TRAF7)  
Several reports have demonstrated that Robo4 is involved in the endothelial response to inflammation. Robo4 prevents vascular leakage in an endotoxemia mouse model via TRAF7. Unlike other TRAF family proteins, TRAF7 lacks the conserved TRAF-C domain, which is responsible for binding to TNF receptors and instead contains a WD40 repeat domain. TRAF7 modulates the activation of nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1) in response to inflammatory stimuli. Robo4 relocates TRAF7 near the nucleus via the Robo4 intracellular domain, which is essential for preventing endothelial permeability. Previous reports have shown that Robo4 shuttles between the plasma membrane and endosome-like compartments. These results indicate that Robo4 regulates the subcellular localization of TRAF7 by intracellular shuttling, subsequently controlling its function.

The role of TRAF7 in vascular permeability is not fully understood. TRAF7 potentially regulates vascular permeability via ubiquitination of binding proteins. TRAF7 contains the RING finger domain, which is common to several ubiquitin E3-ligases. Previous reports have demonstrated that TRAF7 is involved in the ubiquitination of NF-κB pathway molecules, NF-κB essential modulator (NEMO), p65, and several transcription factors, including cellular FADD-like IL-1β-converting enzyme-inhibitory protein (c-FLIP), c-Myb, and krüppel-like factor 4 (KLF4). Furthermore, proteomic studies have identified several TRAF7-interacting proteins, including Mitogen-activated protein kinase kinase kinase 3 (MEKK3) and Rac1. Interestingly, these substrates and interacting proteins are involved in regulating vascular leakage. These results suggest that Robo4 regulates vascular permeability by modulating the activity of these TRAF7-related proteins (Fig. 3).

4. ROBO4 AS A POTENTIAL THERAPEUTIC TARGET

VEGF signaling is one of the targets that suppress patho-

---

**Fig. 2. Robo4 Regulates Endothelial Permeability by Acting as a Membrane-Associated Ligand for Unc5B**

The extracellular domain of Robo4 interacts with and activates Unc5B. Unc5B activation attenuates the phosphorylation of VEGFR2 Y951, but not Y1175, in response to VEGF, resulting in decreased vascular leakage. Abbreviations: Robo, Roundabout; VE, vascular endothelial; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2. (Color figure can be accessed in the online version.)

**Fig. 3. Robo4 Regulates Endothelial Permeability via TRAF7**

The intracellular domain of Robo4 interacts with TRAF7, thus sequestering and anchoring it close to the nuclei in endothelial cells. Robo4 suppresses the destabilization of VE-cadherin induced by TNFα in a TRAF7-dependent manner. Abbreviations: Robo, Roundabout; TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; TRAF7, tumor necrosis factor receptor-associated factor 7; VE, vascular endothelial. (Color figure can be accessed in the online version.)
logical vascular leakage and angiogenesis. In fact, stabilization of the pathological vasculature by inhibiting VEGF signaling is an effective treatment strategy against various diseases, including cancer, 23–34 ocular diseases, 25 and diabetic nephropathy. 26 However, because VEGF signaling regulates vascular development and maintenance under physiological conditions, complete inhibition of VEGF signaling by the antibodies against VEGF and VEGF-R2 induces adverse effects in the cardiovascular system. 27 In contrast, Robo4 stabilizes the pathological vasculature without affecting vascular development and maintenance. Thus, Robo4 could be a useful therapeutic target that specifically suppresses VEGF signaling under pathological conditions.

Several therapeutic studies have reported the use of molecules that activate Robo4 signaling. Robo4-Fe, which activates Unc5B signaling, suppresses basic fibroblast growth factor-driven angiogenesis in a mouse subcutaneous sponge model. 48 A humanized antibody against Robo4, DS-7080a, which possibly modulates Robo4 function, ameliorates neovascular age-related macular degeneration in cynomolgus monkeys 49 Annexin A2, as a potential ligand for Robo4, controls blood-brain barrier integrity. 70 These reports suggest that the development of molecules targeting Robo4 signaling will provide a new therapeutic strategy for the treatment of pathological vascular angiogenesis and permeability.

5. CONCLUSION AND PERSPECTIVES

Robo4 stabilizes the vasculature under pathological conditions by reducing vascular permeability and promoting angiogenesis. Furthermore, Robo4 stabilizes blood vessels by interacting with multiple proteins, including SLITs-Robo1, Unc5B, and TRAF7. Robo4 has been suggested to modulate the activity of interacting proteins in a context-dependent manner. Robo4 could be a potential therapeutic target for stabilizing the pathological vasculature. Further studies on Robo4 function and its activating molecules will accelerate the development of novel drugs against various vascular diseases.

Acknowledgments This work was supported by the Japan Society for the Promotion of Science KAKENHI (Grant Nos. 20H03382 and 20K21481), the Japan Research Foundation for Clinical Pharmacology, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Takeda Science Foundation.

Conflict of Interest The authors declare no conflict of interest.

REFERENCES

1) Claesson-Welsh L, Dejana E, McDonald DM. Permeability of the endothelial barrier: identifying and reconciling controversies. Trends Mol. Med., 27, 314–331 (2021).
2) van Buul JD, Timmerman I. Small Rho GTPase-mediated actin dynamics at endothelial adherens junctions. Small GTPases, 7, 21–31 (2016).
3) Weis SM, Chereh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature, 437, 497–504 (2005).
4) Mehta D, Ravindran K, Kuebler WM. Novel regulators of endothelial barrier function. Am. J. Physiol.Lung Cell. Mol. Physiol., 307, L924–L935 (2014).
5) Claesson-Welsh L, Vascular permeability—the essentials. Ups. J. Med. Sci., 120, 135–143 (2015).
6) Park-Windheil C, D’Amore PA. Disorders of vascular permeability. Annu. Rev. Pathol., 11, 251–281 (2016).
7) Pappu KS, Zipursky SL. Axon guidance: repulsion and attraction in roundabout ways. Curr. Biol., 20, R400–R402 (2010).
8) Blockus H, Chedotal A. Slit-Robo signaling. Development, 143, 3037–3044 (2016).
9) Bisik F, McCarthy AA. Structure and function of roundabout receptors. Subcell. Biochem., 93, 291–319 (2019).
10) Seege M, Teyar G, Ferres-Marco D, Goodman CS. Mutations affecting growth cone guidance in drosophila: genes necessary for guidance toward or away from the midline. Neuron, 10, 409–426 (1993).
11) Huminecki L, Gorn M, Suchting S, Poulsom R, Bicknell R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics, 79, 547–552 (2002).
12) Park KW, Morrison CM, Sorensen LD, Jones CA, Rao Y, Chien CB, Wu JY, Ureens LD, Li DY. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev. Biol., 261, 251–267 (2003).
13) Bedell VM, Yeo S-Y, Park KW, Chung J, Seth P, Shivalingappa V, Zhao J, Obaga J, Sakhatme VP, Drummond JA, Li DY, Ramchandran R. Roundabout4 is essential for angiogenesis in vivo. Proc. Natl. Acad. Sci. U.S.A., 102, 6373–6378 (2005).
14) Okada Y, Yano K, Jin E, Funahashi N, Kitayama M, Doi T, Spokes K, Beeler DL, Shih S-C, Okada H, Danilov TA, Maynard E, Minami T, Oetttgen P, Aird WC. A three-kilobase fragment of the human Robo4 promoter directs cell type-specific expression in endothelium. Circ. Res., 100, 1712–1722 (2007).
15) Okada Y, Jin E, Nikolova-Krstevski V, Yano K, Liu J, Beeler D, Spokes K, Kitayama M, Funahashi N, Doi T, Janes L, Minami T, Oetttgen P, Aird WC. A GABP-binding element in the Robo4 promoter is necessary for endothelial expression in vivo. Blood, 112, 2336–2339 (2008).
16) Okada Y, Funahashi N, Tanaka T, et al. Endothelial cell-specific expression of roundabout 4 is regulated by differential DNA methylation of the proximal promoter. Arterioscler. Thromb. Vasc. Biol., 34, 1531–1538 (2014).
17) Yadav SS, Narayan G. Role of ROBO4 signalling in developmental and pathological angiogenesis. BioMed Res. Int., 2014, 683025 (2014).
18) Dai C, Gong Q, Cheng Y, Su G. Regulatory mechanisms of Robo4 and their effects on angiogenesis. BioSci. Rep., 39, BSR20190513 (2019).
19) Kaur S, Samant GV, Pramanik K, Loscombe PW, Pendrak ML, Roberts DD, Ramchandran R. Silencing of directional migration in roundabout4 knockdown endothelial cells. BMC Cell Biol., 9, 61 (2008).
20) Seldon H, Andre M, Legg JA, Heal P, Herbert JM, Sainson R, Sharrma AS, Kitajewski JK, Heath VL, Bicknell R. Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors. FASEB J., 23, 513–522 (2009).
21) Kaur S, Castellone MD, Bedell VM, Konar M, Gutkind JS, Ramchandran R. Robo4 signaling in endothelial cells implies attraction guidance mechanisms. J. Biol. Chem., 281, 11347–11356 (2006).
22) Jones CA, London NR, Chen H, Park KW, Sauvaget D, Stockton RA, Wytche JD, Suh W, Linreui-Lahargue F, Mukouyama Y, Lindblom P, Seth P, Friaas A, Nishiya N, Ginsberg MH, Gerhardt H, Zhang K, Li DY. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat. Med., 14, 448–453 (2008).
23) Zhang F, Prahst C, Mathivet T, Pibouin-Fragner L, Zhang J, Genet G, Tong R, Dubrac E, Eichmann A. The Robo4 cytoplasmic domain is dispensable for vascular permeability and neovascularization.
24) Zhao H, Ahirwar DK, Oghumu S, Wilkie T, Powell CA, Nasser MW, Satoskar AR, Li DY, Ganju RK. Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis. *Mol. Oncol.*, 10, 272–281 (2016).

25) Liao W-X, Laurent LC, Agent S, Hodges J, Chen D. Human placental expression of SLIT/ROBO signaling cues: effects of preeclampsia and hypoxia. *Biol. Reprod.*, 86, 111 (2012).

26) Tanaka T, Maekawa N, Kashio T, Izawa K, Ishiba R, Shirakura K, Ishimoto K, Hino A, Aird WC, Dori T, Okada Y. Tumor necrosis factor α induces the expression of the endothelial cell-specific receptor roundabout4 through the nuclear factor-κB pathway. *Biol. Pharm. Bull.*, 40, 504–509 (2017).

27) Xie J, Gong Q, Liu Q, Liu Z, Tian R, Cheng Y, Su G. Transcription factor SP1 mediates hyperglycemia-induced upregulation of roundabout4 in retinal microvascular endothelial cells. *Gene*, 616, 31–40 (2017).

28) Koch AW, Mathivet T, Larrivée B, et al. Robo4 maintains tumor integrity and inhibits angiogenesis by interacting with UNC5B. *Dev. Cell.*, 20, 33–46 (2011).

29) Shirakura K, Ishiba R, Kashio T, Funatsu R, Tanaka T, Fukada S, Ishimoto K, Hino N, Kodoh M, Ayo T, Fujio Y, Yano K. Dori T, Aird WC, Okada Y. The Robo4-TRAF3 complex suppresses endothelial hyperpermeability in inflammation. *J. Cell. Sci.*, 132, gs220228 (2019).

30) Troullinaki M, Chen LS, Witt A, Pyzina I, Phieljer I, Kortzelt L, Chmeler J, Sprott D, Gercken M, Boutsiakos M, Chavakis T, Chatzigeorgiou A. Robo4-mediated pancreatic endothelial integrity decreases inflammation and islet destruction in autoimmune diabetes. *FASEB J.*, 34, 3336–3346 (2020).

31) London NR, Zhu W, Bozza FA, Smith MCP, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA, Li DY. Targeting Robo4-dependent Slt signaling to survive the cytokine storm in sepsis and septic shock. *Cell*, 172, 23ra19 (2019).

32) Cheng Y, Liu Z, Wang S, Wang C, Qi S, Zhao J, Tian R, Su G. Effect of Robo4 on retinal endothelial permeability. *Curr. Eye Res.*, 38, 128–136 (2013).

33) Gould RA, Aziz H, Woods CE, et al. ROBO4 variants predispose individuals to bicuspid aortic valve and thoracic aortic aneurysm. *Nat. Genet.*, 51, 42–50 (2019).

34) Vestweber D. How leukocytes cross the vascular endothelium. *Nat. Rev. Immunol.*, 15, 692–704 (2015).

35) Vestweber D. Relevance of endothelial junctions in leukocyte extravasation and vascular permeability. *Ann. N. Y. Acad. Sci.*, 1257, 184–192 (2012).

36) Weis S, Cui J, Barnes L, Cheresh DA. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. *J. Cell Biol.*, 187, 223–229 (2009).

37) Kashio T, Shirakura K, Kinoshita M, Morita M, Ishiba R, Muraoka K, Kanbara T, Tanaka M, Funatsu R, Hino N, Koyama M, Suzukou K, Yoshitaka Y, Aoshi T, Dori T, Okada Y. HDAC inhibitor, MS-275, decreases inflammation and islet destruction in autoimmune diabetes. *FASEB J.*, 34, 3336–3346 (2020).

38) Smith-Berdan S, Nguyen A, Hong MA, Forsberg EC. ROBO4-Mediated Vascular Integrity Regulates the Directionality of Hematopoietic Stem Cell Trafficking. *Stem Cell Reports*, 4, 255–268 (2015).

39) Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, Lim CJ, Chen H, Zhang Q, Schultz PG, Hayallah AM, Thomas KR, Fanulok M, Zhang K, Ginsberg MH, Li DY. Slt2-Robo4 signaling promotes vascular stability by blocking Arf6 activity. *Nat. Cell. Biol.*, 11, 1325–1331 (2009).

40) Zhang B, Dietrich UM, Geng J-G, Bicknell R, Esko JD, Wang L. Repulsive axon guidance molecule Slt3 is a novel angiogenic factor. *Blood*, 114, 4300–4309 (2009).

41) Genet N, Boyé K, Mathivet T, Ola R, Zhang F, Dubrac A, Li J, Genet N, Henrique Geraldo L, Benedetti L, Künzel S, Pibouin-Fragner L, Thomas F-L, Eichmann A. Endothelin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis. *Nat. Commun.*, 10, 2350 (2019).

42) Rama N, Dubrac A, Mathivet T, Ni Chárthaigh R-A, Genet G, Cristofaro B, Pibouin-Fragner L, Ma L, Eichmann A, Chédotal A. Slt2 signaling through Robo1 and Robo2 is required for retinal neovascularization. *Nat. Med.*, 21, 483–491 (2015).

43) Li S, Huang L, Sun Y, Bai Y, Yang F, Yu W, Li F, Zhang Q, Wang B, Geng J-G, Li X. Slt2 promotes angiogenic activity via the Robo1-VEGFR2-ERK1/2 pathway in both in vivo and in vitro studies. *Invest. Ophthalmol. Vis. Sci.*, 56, 5210–5217 (2015).

44) Guo S-W, Zheng Y, Lu Y, Liu X, Geng J-G. Slt2 overexpression results in increased microvesSEL density and lesion size in mice with induced endometriosis. *Reprod. Sci.*, 20, 285–298 (2013).

45) Wang X, Bove AM, Simone G, Ma B. Molecular basis of VEGFR-2-mediated physiological function and pathological role. *Front. Cell. Dev. Biol.*, 8, 599281 (2020).

46) Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signaling. *Nat. Rev. Mol. Cell Biol.*, 17, 611–625 (2016).

47) Dubrac A, Genet N, Ola R, Zhang F, Pibouin-Fragner L, Han J, Zhang J, Thomas F-L, Chédotal A, Schwartz M. A. Eichmann A. Targeting NCk-mediated endothelial cell front-rear polarity inhibits neovascularization. *Circulation*, 133, 409–421 (2016).

48) Suzuki T, Heil P, Taitis K, Stewart LM, Bicknell R. Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. *FASEB J.*, 19, 121–123 (2005).

49) Morlot C, Thielens NM, Ravelli RBG, Hemrika W, Romijn RA, Gros P, Cusack S, McCarthy AA. Structural insights into the Slt2-Robo complex. *Proc. Natl. Acad. Sci. U.S.A.*, 104, 14923–14928 (2007).

50) Hivert B, Liu Z, Chuang CY, Doherty P, Sundaresan V. Robo1 and Robo2 are homophilic binding molecules that promote axonal growth. *Mol. Cell. Neurosci.*, 21, 534–545 (2002).

51) Evans TA, Bashaw GJ. Functional diversity of Robo receptor immunoglobulin domains promotes distinct axon guidance decisions. *Curr. Biol.*, 20, 567–572 (2010).

52) Enomoto S, Mitsu K, Kawanuma I, Iwanari H, Daigo K, Horiiuchi K, Minami I, Kodama T, Hamakubo T. Suppression of Slit2/Robo1-mediated physiological function and pathological role. *FASEB J.*, 34, 3336–3346 (2020).

53) London NR, Zhu W, Bozza FA, Smith MCP, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA, Li DY. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and septic shock. *Cell*, 172, 23ra19 (2019).

54) Smith-Berdan S, Nguyen A, Hong MA, Forsberg EC. ROBO4-Mediated Vascular Integrity Regulates the Directionality of Hematopoietic Stem Cell Trafficking. *Stem Cell Reports*, 4, 255–268 (2015).

55) Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, Lim CJ, Chen H, Zhang Q, Schultz PG, Hayallah AM, Thomas KR, Fanulok M, Zhang K, Ginsberg MH, Li DY. Slt2-Robo4 signaling promotes vascular stability by blocking Arf6 activity. *Nat. Cell. Biol.*, 11, 1325–1331 (2009).

56) Zhang B, Dietrich UM, Geng J-G, Bicknell R, Esko JD, Wang L. Repulsive axon guidance molecule Slt3 is a novel angiogenic factor. *Blood*, 114, 4300–4309 (2009).

57) Smith RH, Norinjoj I, Gordon E, Andre H, Dejana E, Vestweber D, Kvant A, Claesson-Welsh L. VEGFR2 pY949 signaling regulates adherens junction integrity and metastatic spread. *Nat. Commun.*, 7, 1–16 (2016).

58) Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. Essential role of Fak-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. *Proc. Natl. Acad. Sci. U.S.A.*, 102, 1076–1081.
59) Zhao H, Anand AR, Ganju RK. Slit2-Robo4 pathway modulates lipopolysaccharide-induced endothelial inflammation and its expression is dysregulated during endotoxemia. *J. Immunol.*, 192, 385–393 (2014).

60) Shirakura K, Ishiba R, Kashio T, Sakai M, Fukushima Y, Yamamoto N, Manabe S, Shigesada N, Tanaka T, Hino N, Aird WC, Doi T, Okada Y. Endothelial Robo4 regulates IL-6 production by endothelial cells and monocytes via a crosstalk mechanism in inflammation. *Biochem. Biophys. Res. Commun.*, 495, 801–806 (2018).

61) Xie P. TRAF molecules in cell signaling and in human diseases. *J. Mol. Signal.*, 8, 7 (2013).

62) Zotti T, Vito P, Stilo R. The seventh ring: exploring TRAF7 functions. *J. Cell. Physiol.*, 227, 1280–1284 (2012).

63) Xu L-G, Li L-Y, Shu H-B. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. *J. Biol. Chem.*, 279, 17278–17282 (2004).

64) Yoshida H, Jono H, Kai H, Li J-D. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7. *J. Biol. Chem.*, 280, 41111–41121 (2005).

65) Zotti T, Uva A, Ferravante A, Vessichelli M, Ceccarelli M, Vito P, Stilo R. TRAF2 protein promotes Lys-29-linked polyubiquitination of IκB kinase (IKKγ)/NF-κB essential modulator (NEMO) and p65/RelA protein and represses NF-κB activation. *J. Biol. Chem.*, 286, 22924–22933 (2011).

66) Scudiero I, Zotti T, Ferravante A, Vessichelli M, Reale C, Masone MC, Leonardi A, Vito P, Stilo R. Tumor necrosis factor (TNF) receptor-associated factor 7 is required for TNFα-induced Jun NH2-terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein. *J. Biol. Chem.*, 287, 6053–6061 (2012).

67) Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. *Nat. Cell Biol.*, 6, 97–105 (2004).

68) He H, Wu Z, Li S, Chen K, Wang D, Zou H, Chen H, Li Y, Liu Z, Qu C. TRAF7 enhances ubiquitin-degradation of KLF4 to promote hepatocellular carcinoma progression. *Cancer Lett.*, 469, 380–389 (2020).

69) Morita Y, Kane-Ishii C, Nomura T, Ishii S. TRAF7 sequesters c-Myc to the cytoplasm by stimulating its sumoylation. *Mol. Biol. Cell.*, 16, 5433–5444 (2005).

70) Fisher OS, Deng H, Liu D, Zhang Y, Wei R, Deng Y, Zhang F, Louvi A, Turk BE, Boggon JJ, Su B. Structure and vascular function of MEKK3–cerebral cavernous malformations 2 complex. *Nat. Commun.*, 6, 7937 (2015).

71) Spindler V, Schlegel N, Waschke J. Role of GTPases in control of microvascular permeability. *Cardiovasc. Res.*, 87, 243–253 (2010).

72) Kisseleva T, Song L, Vorontchikhina M, Feirt N, Kitajewski J, Schindler C. NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancer. *J. Clin. Invest.*, 116, 2955–2963 (2006).

73) Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. *J. Clin. Oncol.*, 31, 2205–2218 (2013).

74) Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. *Cancer Cell.*, 26, 605–622 (2014).

75) Campostrino PA, Atello LP, Rosenfeld PJ. Anti–vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside. *Ophthalmology.*, 123 (10S), S78–S88 (2016).

76) Tanabe K, Wada J, Sato Y. Targeting angiogenesis and lymphangiogenesis in kidney disease. *Nat. Rev. Nephrol.*, 16, 293–303 (2020).

77) Porta M, Strigilia E. Intravitreal anti-VEGF agents and cardiovascular risk. *Intern. Emerg. Med.*, 15, 199–210 (2020).

78) Isumi Y, Hayashi S, Inoue T, Yoshigae Y, Sato T, Hasegawa J, Agatsuma T. DS-7080a, a selective anti-ROBO4 antibody, shows anti-angiogenic efficacy with distinctly different profiles from anti-VEGF agents. *Transl. Vis. Sci. Technol.*, 9, 7 (2020).

79) Li W, Chen Z, Yuan J, Yu Z, Cheng C, Zhao Q, Huang L, Hajar KA, Chen Z, Lo EH, Dai H, Wang X. Annexin A2 is a Robo4 ligand that modulates ARF6 activation-associated cerebral transendothelial permeability. *J. Cereb. Blood Flow Metab.*, 39, 2048–2060 (2019).